Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cerilliant
AstraZeneca
Johnson and Johnson
Colorcon
Healthtrust
Medtronic
Federal Trade Commission
Accenture

Generated: January 16, 2019

DrugPatentWatch Database Preview

Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir and what is the scope of dasabuvir sodium; ombitasvir; paritaprevir; ritonavir freedom to operate?

Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir has five hundred and sixteen patent family members in fifty-one countries.

One supplier is listed for this compound.

Summary for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir

US Patents and Regulatory Information for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2368890/01 Switzerland ➤ Sign Up PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
90012-9 Sweden ➤ Sign Up PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119
2015013 Lithuania ➤ Sign Up PRODUCT NAME: DASABUVIRUM; REGISTRATION NO/DATE: EU/1/14/983 20150115
2340029/01 Switzerland ➤ Sign Up PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Deloitte
Daiichi Sankyo
Accenture
Cerilliant
Teva
Colorcon
Chubb
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.